Key highlights
12 May 2023 – 1 mins read
LinkedIn
Twitter
Facebook
Understanding the true impact of living with FOP
This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23,
Explore more by category
Showing: 1 – 10 of 45 stories
27 October 2022 – 1 mins read
A word from CEO David Loew
“Our growth platforms have delivered strong sales performance, reflecting improving commercial execution and the strength for our portfolio.” CEO David Loew
14 October 2022 – 2 mins read
Ipsen becomes a founding sponsor of the second Biolabs innovation hub in Europe at Hopital Hotel Dieu, AP-HP
Ipsen announces that it becomes a founding sponsor of the second Biolabs innovation brain hub in Europe at Hopital Hotel Dieu, AP-HP, in Paris, France. The announcement builds on a 2018 commitment to a partnership with Biolabs for the development of a netw
11 October 2022 – 3 mins read
The Ixcellence Network®: celebrating 10 years of progress in improving the standard of care for patients living with debilitating neurological disorders
Continuing medical education is vital to maintaining the quality of clinical practice, which in turn can improve patient outcomes. As a pioneer in botulinum neurotoxin type A (BoNT-A) treatment, Ipsen has worked with a scientific steering committee of inte
05 September 2022 – 5 mins read
‘A Life in a Day’: the realities of living with FOP
I was honored to be invited to take on the challenge to live ‘A Life in a Day of a patient with FOP’ – but also apprehensive. The challenge simulated a day spent living as someone who has fibrodysplasia ossificans progressiva (FOP). FOP is a debilita
01 September 2022 – 2 mins read
Ipsen receives SBTi approval for climate targets
In October 2021, Ipsen pledged ambitious action on climate change. Today, we announce that Ipsen’s Climate Targets were approved by The Science Based Target initiative (SBTi). This approval confirms that our greenhouse gas (GHG) emission reduction target
Ipsen’s partnership with Marengo
Find out more about how we approach partnerships at Ipsen, where every program is a priority within our pipeline. We sat down with Zhen Su, CEO Marengo, to discuss our partnership and how we undertake a one team approach to accelerate innovation for the pa
Ipsen’s 2022 Integrated Annual Report now available
2022 was a year of focus, momentum and growth at Ipsen. Learn about the progress we made and download the 2022 Integrated Annual Report here.
Collette: finding community through PBC
Collette spent almost 20 years going back and forth between different doctors and treatments, before she was finally diagnosed with PBC.
Caitlin: learning to accept care as a caregiver
In September 2012, when she was 21, Caitlin received news every child dreads: her father had been diagnosed with pancreatic cancer and had been given three months to live.
Steve: taking action against kidney cancer
Steve has been diagnosed with kidney cancer twice. After initial success with a nephrectomy, his cancer returned in January 2018. This time, his doctor said there was no treatment available. “He advised I would probably be put on life-extending drugs,”
Diana: Taking spasticity in stride
Diana was a full-time journalist when, at the age of 34, she experienced a stroke that impacted her movement and left her with spasticity.
Fireside Chat: Innovation and Policy Change in Rare Diseases
The rare disease community continues to strive for innovative solutions to meet patient needs and ensure no person living with a rare disease is left behind.
Applications now open for the 2023 Golden Ticket Competition
As part of our commitment to accelerating transformative research and development, we’re excited to announce that our Golden Ticket Competition is now open! Through our continued partnership with Biolabs, we’re delighted to be offering the brightest mi
Understanding the true impact of living with FOP
This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23,
Rethinking risk factors this Liver Cancer Awareness Month
Learn how to engage with our campaign and help protect your liver health. Every year, Liver Cancer Awareness Month (LCAM) is an opportunity to bring the sixth most prevalent cancer globally to the forefront of conversation, promoting awareness and the impo